Clinical trials network strives for standardization.

FDG is the most commonly used radiopharmaceutical in clinical oncology PET studies and is used in numerous clinical trials. In clinical trials, it is important to conduct the studies in a standardized fashion that facilitates accurate interpretation of the study data, particularly when compared to similar trials. In an effort to create one protocol that would be widely acceptable for virtually all oncology clinical trials incorporating FDG imaging, the SNM Clinical Trials Network (CTN) convened a meeting with 25 representatives from key groups around the world. Using the summary document developed by the UPICT group, we addressed a number of key items and completed review of approximately three-fourths of the proposed topics. The discussion produced agreement on several significant points including management of diabetic patients, a minimum fasting time of 6 hours and a target imaging time at 60 minutes (55-75 min). Once all remaining points have been discussed and agreement reached, the final protocol will be organized into a jointly-authored document and submitted for publication.